World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Best Female Scientists 115 689 656 418 394 515 124610
Medicine 123 3254 3033 1794 1650 515 136859

Julie R. Brahmer publications per year

The chart shows the history of publications by Julie R. Brahmer between 1998 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Julie R. Brahmer published across 29 years, from 1998 to 2026, averaging 27.8 papers a year. Output peaked at 162 publications in 2023. 57 of the 805 publications appeared in the last two years.

No. of publications
50 100 150
Bar chart. Horizontal axis: year, 1998 to 2026. Vertical axis: number of publications, 0 to 162. Peak 162 publications in 2023. 1998: 2 publications 1999: 0 publications 2000: 0 publications 2001: 0 publications 2002: 1 publication 2003: 2 publications 2004: 5 publications 2005: 12 publications 2006: 18 publications 2007: 24 publications 2008: 14 publications 2009: 12 publications 2010: 9 publications 2011: 8 publications 2012: 17 publications 2013: 23 publications 2014: 31 publications 2015: 26 publications 2016: 33 publications 2017: 39 publications 2018: 42 publications 2019: 46 publications 2020: 28 publications 2021: 49 publications 2022: 34 publications 2023: 162 publications 2024: 111 publications 2025: 53 publications 2026: 4 publications
1998 2026

805 publications in total across all disciplines

View publications per year as a table
Julie R. Brahmer: publications per year, 1998 to 2026
Year Publications
1998 2
1999 0
2000 0
2001 0
2002 1
2003 2
2004 5
2005 12
2006 18
2007 24
2008 14
2009 12
2010 9
2011 8
2012 17
2013 23
2014 31
2015 26
2016 33
2017 39
2018 42
2019 46
2020 28
2021 49
2022 34
2023 162
2024 111
2025 53
2026 4
Total 805
Download as CSV

Julie R. Brahmer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Julie R. Brahmer sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 501–520 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 515 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617 515
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Julie R. Brahmer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Julie R. Brahmer sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 122–123 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 123 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255 123
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Julie R. Brahmer is affiliated with Johns Hopkins University in the United States and has a significant body of work within the field of Medicine. Their research focus primarily encompasses oncology, pulmonary and respiratory medicine, cancer research, molecular biology, and immunology.

The scientist's frequent publication venues include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Journal of Thoracic Oncology
  • Journal for ImmunoTherapy of Cancer
  • Annals of Oncology

Julie R. Brahmer's main fields of study are:

  • Medicine

Within medicine, their subfields of study are:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Molecular Biology
  • Immunology

The scientist's research covers multiple topics, including:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • CAR-T cell therapy research

Frequent coauthors collaborating with Julie R. Brahmer include:

  • Patrick M. Forde
  • Valsamo Anagnostou
  • Kristen A. Marrone
  • Jarushka Naidoo
  • Christine L. Hann

Notable recent papers authored or coauthored by Julie R. Brahmer include:

  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events, 2021, Journal for ImmunoTherapy of Cancer
  • Immune-related adverse events of checkpoint inhibitors, 2020, Nature Reviews Disease Primers
  • Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%, 2021, Journal of Clinical Oncology
  • Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer, 2021, Journal of Clinical Oncology
  • Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers, 2021, Nature

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

    H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel

  • Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

    Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

  • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    Julie Brahmer;Karen L Reckamp;Paul Baas;Lucio Crinò

  • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

    Alan Sandler;Robert Gray;Michael C. Perry;Julie Brahmer

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

    Julie R. Brahmer;Charles G. Drake;Ira Wollner;John D. Powderly

  • Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Matthew D. Hellmann;Tudor-Eliade Ciuleanu;Adam Pluzanski;Jong Seok Lee

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

    Janis M Taube;Alison P. Klein;Julie R Brahmer;Haiying Xu

  • Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

    Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  • Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

    Patrick M. Forde;Jamie E. Chaft;Kellie N. Smith;Valsamo Anagnostou

  • Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Immune-related adverse events of checkpoint inhibitors.

    Manuel Ramos-Casals;Julie R. Brahmer;Margaret K. Callahan;Margaret K. Callahan;Alejandra Flores-Chávez

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

    Daniel D. Von Hoff;Patricia M. LoRusso;Charles M. Rudin;Josina C. Reddy

  • [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

    Christopher G. Azzoli;Sherman Baker;Sarah Temin;William Pao

  • Genome-wide cell-free DNA fragmentation in patients with cancer

    Stephen Cristiano;Alessandro Leal;Jillian Phallen;Jacob Fiksel

  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

    Matthew D. Hellmann;Naiyer A. Rizvi;Jonathan W. Goldman;Scott N. Gettinger

Frequent Co-Authors

Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Scott N. Gettinger
Scott N. Gettinger Yale University
Scott J. Antonia
Scott J. Antonia Duke University
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center
Janis M. Taube
Janis M. Taube Johns Hopkins University
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
Victor E. Velculescu
Victor E. Velculescu Johns Hopkins University School of Medicine
Leora Horn
Leora Horn Vanderbilt University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in healthcare but aren’t sure if a traditional medical degree is the right path, there are several high-demand alternatives to explore. Many prospective students choose to pursue roles as nurses, healthcare administrators, or medical billing specialists, each offering unique benefits and career flexibility.

For those looking for accessible options, there are nursing schools with high acceptance rates, which can be a great entry point into nursing without overly competitive admission processes. Additionally, if you’re seeking streamlined entry into nursing, consider a nursing school that doesn't require teas—eliminating the need for standardized entrance exams.

Interested in the administrative side of healthcare? Pursuing a degree in healthcare administration can open doors to leadership and management roles in hospitals and clinics. Alternatively, specialized fields such as medical billing and coding are both in demand and flexible. Look for medical billing and coding schools that accept fafsa to help ease the financial burden of your studies.

These alternative pathways offer rewarding opportunities in healthcare and can be pursued online, making them accessible and convenient for many students.

Best Scientists Citing Julie R. Brahmer

Trending Scientists

Recently Published Articles